drugset / Trial / NCT02691871
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Phase 1
Unknown
20 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to confirm the safety of Apatinib at a dose level up to 750 mg/d with standard therapy of docetaxel (60 mg/m²) in advanced lung adenocarcinoma patients harboring wild-type EGFR after failure of first line chemotherapy and to determine the recommended dose for the Phase II trial.
Timeline
- Start
- 2016-02
- Primary completion
- 2016-10
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Rivoceranib | Small molecule | 500 mg | — |
| Subject | Rivoceranib | Small molecule | 750 mg | — |
| Background | Docetaxel | Small molecule | 60 mg/m2 | — |